OpenSSL SSL_connect: Connection reset by peer in connection to v2.sherpa.ac.uk:443 PuSH - Publication Server of Helmholtz Zentrum München: Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.

PuSH - Publication Server of Helmholtz Zentrum München

Siekmann, I.-K.* ; Dierck, K.* ; Prall, S.* ; Klokow, M.* ; Strauss, J.* ; Buhs, S.* ; Wrzeszcz, A.* ; Bockmayr, M.* ; Beck, F.* ; Trochimiuk, M.* ; Gottschling, K.* ; Martens, V.* ; Khosh-Naucke, M.* ; Gerull, H.* ; Müller, J.* ; Behrmann, L.* ; Blohm, M.* ; Zahedi, R.P.* ; Jeremias, I. ; Sickmann, A.* ; Nollau, P.* ; Horstmann, M.A.*

Combined inhibition of receptor tyrosine and p21-activated kinases as a therapeutic strategy in childhood ALL.

Blood Adv. 2, 2554-2567 (2018)
Publ. Version/Full Text DOI PMC
Free journal
Receptor tyrosine kinase (RTK)-dependent signaling has been implicated in the pathogenesis of acute lymphoblastic leukemia (ALL) of childhood. However, the RTK-dependent signaling state and its interpretation with regard to biological behavior are often elusive. To decipher signaling circuits that link RTK activity with biological output in vivo, we established patient-derived xenograft ALL (PDX-ALL) models with dependencies on fms-like tyrosine kinase 3 (FLT3) and platelet-derived growth factor receptor β (PDGFRB), which were interrogated by phosphoproteomics using iTRAQ mass spectrometry. Signaling circuits were determined by receptor type and cellular context with few generic features, among which we identified group I p21-activated kinases (PAKs) as potential therapeutic targets. Growth factor stimulation markedly increased catalytic activities of PAK1 and PAK2. RNA interference (RNAi)-mediated or pharmacological inhibition of PAKs using allosteric or adenosine triphosphate (ATP)-competitive compounds attenuated cell growth and increased apoptosis in vitro. Notably, PAK1- or PAK2-directed RNAi enhanced the antiproliferative effects of the type III RTK and protein kinase C inhibitor midostaurin. Treatment of FLT3- or PDGFRB-dependent ALLs with ATP-competitive PAK inhibitors markedly decreased catalytic activities of both PAK isoforms. In FLT3-driven ALL, this effect was augmented by coadministration of midostaurin resulting in synergistic effects on growth inhibition and apoptosis. Finally, combined treatment of PDX-ALL with the ATP-competitive group I PAK inhibitor FRAX486 and midostaurin in vivo significantly prolonged leukemia progression-free survival compared with midostaurin monotherapy or control. Our study establishes PAKs as potential downstream targets in RTK-dependent ALL of childhood, the inhibition of which might help prevent the selection or acquisition of resistance mutations toward tyrosine kinase inhibitors.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
ISSN (print) / ISBN 2473-9529
e-ISSN 2473-9537
Journal Blood advances
Quellenangaben Volume: 2, Issue: 19, Pages: 2554-2567 Article Number: , Supplement: ,
Publisher American Society of Hematology
Publishing Place Washington, DC
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Research Unit Apoptosis in Hematopoietic Stem Cells (AHS)